Metformin
GLP-1Evidence-based breakdown of blood sugar control, weight effects, heart benefits, and side effects—so you know what to expect before taking it.
Based on randomized clinical trials and real-world outcomes.
Proven 25+ years. Modest blood sugar control with excellent safety and long-term track record. Less powerful than newer drugs.
💊 What This Drug Does
🛡️ Safety Profile
Why This Rating
- One of the safest diabetes medications with 25+ years of real-world use
- GI side effects common early but usually temporary and manageable
- Very high long-term safety certainty from decades of data
Safety Breakdown
Common side effects
Diarrhea, nausea, and stomach upset occur in ~30% of people when starting, but usually resolve within weeks. Taking with food helps.
Serious safety concerns
Lactic acidosis is extremely rare (~3 cases per 100,000 people per year). Should not be used if you have severe kidney disease.
How often people stop
People continue metformin long-term at high rates. Early GI upset can occur, but most people adapt and persist.
How hard it is to manage
Oral tablet, simple twice-daily dosing. Minimal drug interactions. Kidney function should be checked annually. No dose escalation needed.
How certain we are long-term
25+ years of worldwide safety data. UKPDS trial followed people for 10+ years. Safety profile is well-established and predictable.
Key Safety Flags
- GI upset common when starting—take with food to minimize
- Monitor kidney function; caution if eGFR <30
- Possible vitamin B12 deficiency with long-term use (easily managed with supplementation)
- Excellent long-term safety track record spanning 25+ years
📊 Blood Sugar Control (Diabetes)
How strong is this result?
Moderate effect, but with unmatched long-term safety track record. First-line treatment for good reason: effective, well-tolerated, and proven over 25+ years. Less dramatic than newer drugs, but more established.
What the studies show
Across several randomized trials (including UKPDS and ADOPT), researchers found −1.0 to −1.5% HbA1c reduction for this outcome.
Who participated: Adults with type 2 diabetes; treatment-naïve to advanced disease; age 40–75; diverse BMI and ethnicity in UKPDS (n=3,234 participants); predominantly White in earlier trials
How confident are we? High confidence (based on older studies)
Study context: Many of these studies were conducted under older care standards, which may limit how well results apply today. Participants varied widely, so results may not apply uniformly to all patients. Long-term data come from older-era trials, which may not reflect current practice.
⚠️ What To Keep In Mind
All clinical evidence comes with limitations. Here's what matters for interpreting this drug's data:
- Limited evidence beyond 2 years of use.
- These trials used methods from the 1990s-2000s. Care standards and patient populations have changed since then.
- All trials consistently showed the main outcome across different populations.
- Trial participants were primarily middle-aged and White. Results may not apply to younger, more diverse populations.